Table 2 Characteristic of patients in derivation and validation cohort
Variables | Derivation cohort (n = 323) | Validation cohort (n = 81) | ||||
|---|---|---|---|---|---|---|
CLNM group (n = 139) | NCLNM group (n = 184) | P-value | CLNM group (n = 33) | NCLNM group (n = 48) | P-value | |
Sex | 0.808 | 0.912 | ||||
 Male | 41 (29.5%) | 52 (28.3%) | 10 (30.3%) | 14 (29.2%) | ||
 Female | 98 (70.5%) | 132 (71.7%) | 23 (69.7%) | 34 (70.8%) | ||
Age, year | 0.313 | 0.503 | ||||
 < 45 | 49 (35.3%) | 75 (40.8%) | 10 (30.3%) | 18 (37.5%) | ||
 ≥ 45 | 90 (64.7%) | 109 (59.2%) | 23 (69.7%) | 30 (62.5%) | ||
HT | 0.368 | 0.654 | ||||
 Yes | 55 (39.6%) | 82 (44.6%) | 16 (48.5%) | 25 (52.1%) | ||
 No | 84 (60.4%) | 102 (55.4%) | 17 (51.5%) | 23 (47.9%) | ||
Tumor size, mm | 0.022 | 0.055 | ||||
 < 5 | 34 (24.5%) | 67 (36.4%) | 7 (21.2%) | 20 (41.7%) | ||
 ≥ 5 | 105 (75.5%) | 117 (63.6%) | 26 (78.8%) | 28 (58.3%) | ||
Multifocality | 0.620 | 0.524 | ||||
 Yes | 62 (44.6%) | 77 (41.8%) | 14 (42.4%) | 17 (35.4%) | ||
 No | 77 (55.4%) | 107 (58.2%) | 19 (57.6%) | 31 (64.6%) | ||
Boundary | 0.034 | 0.414 | ||||
 Clear | 90 (64.7%) | 139 (75.5%) | 22 (66.7%) | 36 (75.0%) | ||
 Unclear | 49 (35.3%) | 45 (24.5%) | 11 (33.3%) | 12 (25.0%) | ||
Aspect ratio | 0.309 | 0.863 | ||||
 < 1 | 76 (54.7%) | 111 (60.3%) | 20 (60.6%) | 30 (62.5%) | ||
 ≧ 1 | 63 (45.3%) | 73 (39.7%) | 13 (39.4%) | 18 (37.5%) | ||
Blood flow | 0.581 | 0.136 | ||||
 Yes | 72 (51.8%) | 101 (54.9%) | 20 (60.6%) | 21 (43.8%) | ||
 No | 67 (48.2%) | 83 (45.1%) | 13 (39.4%) | 27 (56.3%) | ||
Calcification | 0.037 | 0.393 | ||||
 Yes | 79 (56.8%) | 83 (45.1%) | 19 (57.6%) | 23 (47.9%) | ||
 No | 60 (43.2%) | 101 (54.9%) | 14 (42.4%) | 25 (52.1%) | ||
Extrathyroidal extension | 0.008 | 0.337 | ||||
 Yes | 27 (19.4%) | 17 (9.2%) | 5 (15.2%) | 4 (8.3%) | ||
 No | 112 (80.6%) | 167 (90.8%) | 28 (84.8%) | 44 (91.7%) | ||
FN1 expression* | 0.003 | 0.007 | ||||
 High | 103 (74.1%) | 107 (58.2%) | 25 (75.8%) | 22 (45.8%) | ||
 Low | 36 (25.9%) | 77 (41.8%) | 8 (24.2%) | 26 (54.2%) | ||
MT-1 F expression* | < 0.001 | 0.004 | ||||
 High | 30 (21.6%) | 72 (39.1%) | 5 (15.2%) | 22 (45.8%) | ||
 Low | 109 (78.4%) | 112 (60.9%) | 28 (84.8%) | 26 (54.2%) | ||
TFF3 expression* | < 0.001 | 0.057 | ||||
 High | 63 (45.3%) | 119 (64.7%) | 15 (45.5%) | 32 (66.7%) | ||
 Low | 76 (54.7%) | 65 (35.3%) | 18 (54.5%) | 16 (33.3%) | ||